MARKET

ACER

ACER

Acer Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.700
+0.120
+4.65%
After Hours: 2.550 -0.15 -5.56% 18:52 05/11 EDT
OPEN
2.560
PREV CLOSE
2.580
HIGH
2.700
LOW
2.560
VOLUME
60.37K
TURNOVER
--
52 WEEK HIGH
5.84
52 WEEK LOW
2.150
MARKET CAP
38.64M
P/E (TTM)
-1.3102
1D
5D
1M
3M
1Y
5Y
The PC market just had its best Q1 since 2015 and fastest growth in 20 years
Monday's report says that PC sales are "historically" strong at the moment and that a work-from-home PC sales boom may not end as offices and schools reopen.
CNBC.com · 04/12 21:25
Who Has Been Buying Acer Therapeutics Inc. (NASDAQ:ACER) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Simply Wall St. · 03/30 06:23
Acer Therapeutics to Participate in Needham Virtual Healthcare Conference
GlobeNewswire · 03/29 13:30
Notice of Settlement of Derivative Suits
NEWTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS DAVID GIROUX, Derivatively on Behalf of ACER THERAPEUTICS, INC., Plaintiff, v.JASON AMELLO, STEVE ASELAGE, HUBERT BIRNER, JOHN M. DUNN, ...
GlobeNewswire · 03/25 20:05
DJ Acer Therapeutics Shares Up 19% on License Agreement With Relief Therapeutics
Dow Jones · 03/22 14:10
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021 GENEVA and NEWTON, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTIC...
GlobeNewswire · 03/22 13:30
Relief and Acer ink ACER-001 collaboration and license agreement
RELIEF THERAPEUTICS Holding (RLFTF) and Acer Therapeutics (ACER) have entered into a Collaboration and License Agreement (“CLA”) for worldwide development and commercialization of ACER-001, a proprietary powder formulation of sodium
Seekingalpha · 03/22 13:07
Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics
Relief Therapeutics Holding AG (OTCMKTS: RLFTF) and Acer Therapeutics Inc (NASDAQ: ACER) 
Benzinga · 03/22 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACER. Analyze the recent business situations of Acer Therapeutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACER stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 59
Institutional Holdings: 2.80M
% Owned: 19.54%
Shares Outstanding: 14.31M
TypeInstitutionsShares
Increased
2
59.23K
New
8
671.76K
Decreased
8
23.13K
Sold Out
5
97.30K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Independent Director
Stephen Aselage
President/Chief Executive Officer/Director
Christopher Schelling
Chief Financial Officer
Harry Palmin
Vice President - Finance/Controller
Jason Kneeland
Vice President
Stacey Bain
Vice President
Terrie Kellmeyer
Vice President
John Klopp
Vice President
Kristin Mulready
Vice President
Matt Seibt
Other
William Andrews
Director of Marketing
Kim Tharaldsen
Independent Director
Jason Amello
Independent Director
Hubert Birner
Independent Director
John Dunn
Independent Director
Michelle Griffin
Independent Director
Luc Marengere
No Data
About ACER
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Webull offers kinds of Acer Therapeutics Inc stock information, including NASDAQ:ACER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACER stock methods without spending real money on the virtual paper trading platform.